Aerospace Group:

Homeland Security

DoD Awards Morphotek $2.3M to Develop Biowarfare Therapies

DDN

Wednesday, October 3rd, 2007

SHARE:

Morphotek, Inc., a subsidiary of Japanese pharmaceutical company Eisai Co., received $2.3 million in funding from the Department of Defense to support the development of biologic- based monoclonal antibody therapies against biowarfare agents. Under the nine-month contract Morphotek will continue developing the therapies to treat Botulinum neurotoxins. "The further development of these compounds will enable us to advance these leads into clinical studies for validation and registration," says Nicholas Nicolaides, president and CEO of Morphotek.

Pentagon

Amid Questions On Weapons Stockpiles, Caine Says U.S. Has ‘Sufficient’ Munitions For Iran Operation

Pentagon leaders on Wednesday sought to quell concerns over the rate at which the U.S. is employing critical munitions in its military strike campaign against Iran, with lawmakers also pressing […]

Congress

SASC Leaders Criticize Trump’s Defense Strategy, Press Colby On Policy Shifts

Senate Armed Services Committee (SASC) leadership on Tuesday criticized the Trump administration’s new National Defense Strategy (NDS) and pressed the Pentagon’s top policy official to explain the document’s priorities. SASC […]

Congress

Wicker Wants Legislation On DoD’s Equity Investments In Minerals Supply Chain

Legislation regarding equity investments by the Defense Department in critical mineral supply chains is needed to strengthen the larger defense industrial base and demonstrate to the “free market” that the […]

Congress

“Not Sure How They Get To Where They Wanna Be,” Calvert Says of $1.5 Trillion Defense Topline Proposal

As the federal government enters a third week of tardiness in a fiscal 2027 budget release, a big question is how the Pentagon will be able to spend $500 billion […]